Caribou Biosciences Inc. (NASDAQ:CRBU) shares skyrocketed 100% on Monday after the company released promising Phase 1 ...
First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with ...
Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has received ethics board approval for its 12-week Phase 1b GLP-1 study, which focuses on diabetes and weight loss, marking a ...
SUDO-550 demonstrated favorable safety, tolerability, and once-daily pharmacokinetic profile with full central nervous system (CNS) penetration - Achieved exposure levels associated with >90% ...
LUND, SE / ACCESS Newswire / May 23, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced the presentation of biomarker data from its OPTIMIZE-1 clinical trial at the 2025 American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback